Skip to main content

Table 3 Frequencies according to EMA guidelines for 1st line ICI therapy of urothelial cancers

From: Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Scores 28–8 22c3 SP263 SP142 28–8 22c3 SP263 SP142
IC ≥ 5%a (17/63) 27% (11/61) 18% (18/63) 29% (1/63) 2% (10/43) 23% (7/44) 16% (14/43) 33% (1/45) 2%
CPS ≥ 10b (13/63) 21% (12/61) 20% (20/63) 32% (1/63) 2% (10/43) 23% (3/44) 7% (20/43) 47% (1/45) 2%
  1. aatezolizumab; bpembrolizumab